Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

/in /by

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre.

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

/in /by

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer –

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

/in /by

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer –

Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow

/in /by

TORONTO, April 17, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025.

Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow

/in /by

TORONTO, April 17, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025.

Profound Medical AUA 2025 Investor Event Agenda

/in /by

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual Meeting.

Profound Medical AUA 2025 Investor Event Agenda

/in /by

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual Meeting.